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Abstract: In recent years, healthcare has become a fundamental pillar of the level of well-being
of any society. With the aim of improving the lives of countries and societies, in 2015 the United
Nations (UN) approved the 2030 Agenda for Sustainable Development. Among the Sustainable
Development Goals (SDGs) set out in the Agenda are health and well-being (O3) and the reduction
of inequalities (O10). The general objective of this paper is to analyse the impact that the level of
socioeconomic development, as well as the evolution of inequalities, have had on public spending
on health in European Union countries. The research methodology is based on the application of a
regression model and statistical techniques such as sigma convergence, beta convergence and the Gini
index. We can see that the levels of public spending on health per capita, the level of socio-economic
development and the degree of inequality are closely related in these countries. For this reason, we
suggest maintaining sustainable economic growth to reduce the economic disparities between EU
countries, and also the current differences in public spending on health per capita.
Keywords: health policies; level of economic development; sigma convergence; Gini index; SDGs
1. Introduction
The incorporation of sustainability and inequality into the field of social sciences
has recently led to a paradigm shift in contemporary research. Economic and social
studies whose sole objective was the search for economic and utilitarian optimisation have
expired. The incorporation of aspects such as sustainable development and the reduction
of inequalities have marked the current path of social research. Nowadays, the sustainable
nature of the productive activity is being considered more strongly, with a vision more
focused on social conditions, the reduction of inequalities and environmental aspects. The
current aim is mainly to establish a balance between productive activity, the environment
in which it takes place, and human activity.
In 2015, the United Nations (UN) adopted the 2030 Agenda for Sustainable Devel-
opment. This created a new path aimed at improving the lives of countries and societies.
The Agenda incorporates a set of goals that include, among others, eradicating poverty,
reducing inequalities, boosting health and well-being, protecting the planet and ensuring
human prosperity [1–3]. These goals are specifically targeted to be achieved within the
next 10 years. The wealth of projects set out in the 2013 Agenda have been grouped into
the 17 Sustainable Development Goals (SDGs), with the overall aim of creating a better
world not only for current generations but also for the future ones [2]. Thus, the ambitious
SDG agenda requires significant investments in universal health coverage by all countries,
as outlined in SDG3, health and well-being, which would undoubtedly reduce inequalities
between and within countries, as envisaged in SDG10, reducing disparities [4,5].
Universal, public and quality healthcare, as a strategic economic and social sector with
high added value and enormous positive externalities, is one of the basic aspects of the
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Welfare State [6–10]. One of the main concerns of the World Health Organisation (WHO)
and the Member States of the European Union is equity in access to health services. In
this respect, the public sector plays an essential role in trying, on the one hand, to ensure
equality of opportunity among citizens and, on the other hand, to improve the level of
well-being of society. Despite the generalisation of the concept, it is necessary to point out
that guaranteeing equity does not imply access for all citizens to all health services at all
times. There are substantial differences between states in terms of benefits, and there may
even be differences in the range of services that are considered acceptable within a country
(e.g., at a regional level). Each health system must have the capacity to establish criteria
that clearly define a reasonable and financially affordable package of services to which to
link the principle of equity of access.
The sustainability of the welfare state has recently become a controversial issue. This
discussion does not stem exclusively from the period of the economic and financial cri-
sis experienced since 2007, but dates back to the 1990s [9]. However, depending on its
severity and time span, an economic crisis often affects public services such as health and
education [11–15]. Indeed, public health seems to have been particularly vulnerable to bud-
get cuts in the European Union, as has become evident since the economic crisis [16–18].
Through spending cuts and tax increases, austerity measures adopted by government
authorities have hit the most economically disadvantaged population particularly hard,
through the so-called “social risk effect”. This effect is caused by an increase in unem-
ployment, poverty, homelessness, and other socio-economic risk factors (indirect effect),
and the “health effect”, which comes from cuts to health services, reductions in health
coverage, and restrictions on access to care (direct effect) [19,20]. Thus, health and social
protection spending are often negatively associated with income inequality, so such efforts
positively impact on reducing disparities [21], and reducing health spending could have
severe consequences for health, especially for the most impoverished population [20].
Frequently, socio-economic analysis attempts to diagnose and examine public expen-
diture on health (hereafter PSH) per capita, and two conflicting ideas can be found. On
the one hand, public spending is seen as an element that negatively affects the country’s
economic development. Indeed, according to the recommendations of the European Union,
it is necessary to establish its precise control, so as not to incur a greater public deficit and
public debt, due to the economic effects that this can have not only on a specific country but
also on the Eurozone. On the other hand, as an investment in health, the resources applied
to this public activity are socially and economically beneficial to the country’s citizens,
favouring the achievement of their activities once the potential illness that paralysed this
function has been corrected.
Health and wellbeing are critical drivers of economic and social development, as
they favour increased labour productivity, healthier ageing of the population, and lower
spending on health-related social benefits [22,23]. Besides, advances in technological
equipment can reduce social inequalities in health [24], developing CO2 emission policies
to channel sustainable socio-economic development [25]. Public spending on health also
facilitates preparedness for a possible pandemic, such as the one the planet is currently
experiencing. This would enable sustainable health, as envisaged by implementing the UN
SDGs, and investment in health capital to ensure a more efficient allocation of resources [5].
In this regard, research has attempted to relate health spending and economic growth
under different human capital levels, concluding that when human capital is high, the
economic impact on health spending and economic growth increases significantly [26].
With prior attention to the second aspect mentioned above, this paper aims to study
whether health spending in European Union countries is conditioned by their level of
socio-economic development. To this end, this general objective is broken down into three
specific objectives: firstly, to investigate the relationship between PSH per capita and GDP
per capita; secondly, to study the level of convergence experienced by these two variables;
and thirdly, to analyse the evolution experienced by inequalities in the level of income per
capita, and their influence on PSH in the context of the countries of the European Union.
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This analysis will make it possible to observe whether the dynamics of cohesion in
PSH have been similar in the European Union countries as a whole. In other words, it
will help to see whether European inhabitants are in a better situation in this respect, or
whether, on the contrary, the evolution of health spending has been more unequal in the
period analysed (2010–2018). The latter could be causing certain disparities between people
living in the same supranational territory, depending on their country of residence. This
will allow us to deduce a pattern to distinguish whether health spending is higher in
countries with a better socioeconomic level, or the other way around. In this sense, the
level of socioeconomic development (measured by GDP per capita) can be established as a
determining factor in health expenditure per capita in the European Union countries as a
whole in the period under study.
In order to address the objectives of this study, we have structured the work as follows.
The second section will describe the methodology used and the statistical sources consulted.
The third reflects the results of the methodology applied to the data examined. The fourth
section contains the discussion on the subject analysed, as well as the bibliographical
sources used in the study. Finally, the last section will highlight the final conclusions from
the research presented.
2. Materials and Methods
Due to the limited availability of homogeneous databases on health expenditure at the
European level, we have consulted Eurostat, the official statistical source of the European
Commission [27]. The aim was to address the objective of this scientific research with
serious and rigorous data, which will enable an in-depth diagnosis of the issue addressed.
However, it is necessary to point out that in the study of some variables we have found
incomplete databases, with data only for a short period of time, such as the statistics on
PSH, with which we only have complete data for the period 2014–2018.
In addition to the description of the data processed, the methodology used to meet the
objectives set out will include an analysis of the evolution experienced by these variables
and their possible links. We have examined this relationship between territorial economic
development and the level of PSH in the countries of the European Union by means of
an econometric estimation. We have also subjected the progress of territorial disparities
to a specific study using indicators such as sigma convergence, beta convergence, the
Gini index, and other applied indices to examine whether territorial differences have been
reduced or, on the contrary, have intensified in the period under examination.
Sigma convergence (σ) is a measure of dispersion. It can be defined as the progress,
over a given period, of the standard deviation of the logarithm of the GPDpc for the EU











where “ln(GPDpcit)” is the logarithm of the GPDpc at constant prices in the i-th country in
year “t”, “ln(GPDpct)” is the logarithm of the GPDpc at constant prices of the EU countries
as a whole, equivalent to a weighted average of the GPDpc of the member states, and “n”
is the number of EU countries, in our case 28.






= β0 + β1(GPDpci,t−h) + ui,t (2)
where GPDpci,t-1 and GPDpci,t represent the per capita income of the i-th country at the
beginning and end of the period considered, respectively, β0 is the constant term, β1 is the
beta coefficient and ui,t are random disturbances of zero mean and constant variance.
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The econometric estimation of fixed-effects panel data can be represented as follows,
trying to test the following relationship:
log(PSHpcit) = Cit + αlog(GPDpcit) + uit (3)
where Cit is a constant that shows the influence of the rest of the elements that affect the
obtaining of PSH per capita, α is the coefficient that establishes the relationship analysed,
log(PSHpcit) is the logarithm of public health expenditure per capita of country i in year t,
and log(GPDpcit) is the logarithm of the per capita income of country i in period t.
Where necessary, the data have been valued in real terms or at constant prices, by
applying the GDP implicit deflator, which is clearly specified in the tables and graphs
presented. In order to value GDP per capita properly, including the personal distribution
within the EU countries, we have chosen to discount the concentration of GDP per capita
using the following formula:
GDPpcn = GDPpc * (1 − GI) (4)
where GDPpcn is GDP per capita net of the concentration of personal distribution, GDPpc
is GDP per capita and GI is the Gini index, which shows the concentration of income per
capita in each of the EU member countries.
On 31 January 2020, the United Kingdom’s exit from the European Union (popularly
known as “Brexit”) took place. For this reason, the analysis has incorporated not only the
average values for the 28-member European Union, including the United Kingdom, but
also the same data for the 27-member European Union, excluding the United Kingdom.
This facilitates the examination of the issue through analysis of the current composition of
the European Union.
Since 2015, the year in which the UN approved the 2030 Agenda, social agents have
been working to achieve the 17 goals known as SDGs. We have therefore decided to
focus the study on the period 2010–2018, as it is interesting to analyse the situation and
progress of these goals in the phase before the approval of the Agenda, and the dynamics
experienced after its approval and implementation. The latest data officially published by
the European Commission are for 2019, although for some variables there are only data
up to 2018, such as PSH. The grouping into intervals of the two periods considered (2010
to 2014 and 2015 to 2018 or 2019) has been carried out to avoid the fixation of results in
a single year. This technique makes it possible to overcome the deviation that could be
generated in an anomalous figure. The first period considered includes the phase before
the adoption of the SDGs, as well as the economic and financial crisis phase, and the second
one includes the cycle after the adoption of the goals and the recovery of the economy.
3. Results
As explained above, the general objective of this paper is to establish the relationship
between PSH and the explanatory variable GDP per capita or income per capita. Although
current statistical and methodological advances make it possible to evaluate the level of
economic development with other more complex and refined indicators, it is common
in economic literature to use GDP per capita or income per capita as an indicator of the
level of economic development. This variable is composed of the quotient between two
elements: GDP in the numerator and population in the denominator. It should be noted
that the population criterion is usually an element used for the distribution of public health
funds in European countries. Sometimes, population ageing is also taken into account
as a discriminating element in the distribution of resources [28]. Therefore, taking into
account that PSH per capita includes the population in the denominator, it is considered
appropriate to carry out a study of the progress experienced by the population in the
countries of the European Union (Table 1).
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Table 1. Population (number of persons), population density (number of inhabitants per square kilometre), population
growth rate (%).
Countries
Population Population Density CAAGR 1
2010–2014 2015–2019 2010–2014 2015–2019 2010–2014 2015–2019
Belgium 11,047.049 11,350.845 361.87 368.31 0.78 0.48
Bulgaria 7329.730 7101.583 66.41 65.21 −0.60 −0.71
Czechia 10,496.562 10,586.159 133.09 133.64 0.12 0.26
Denmark 5581.149 5740.601 130.02 132.07 0.42 0.64
Germany 80,728.686 82,341.288 225.89 227.88 −0.32 0.56
Estonia 1324.832 1318.080 29.29 29.11 −0.33 0.19
Ireland 4591.445 4784.586 65.78 67.15 0.48 1.19
Greece 11,051.902 10,775.145 83.70 82.30 −0.44 −0.31
Spain 46,642.420 46,602.639 92.19 91.97 0.01 0.26
France 65,336.178 66,767.637 103.19 104.76 0.58 0.21
Croatia 4275.527 4150.387 75.55 74.49 −0.33 −0.89
Italy 59,683.387 60,578.825 197.58 200.29 0.67 −0.18
Cyprus 848.956 858.053 91.77 92.40 1.17 0.84
Latvia 2053.043 1951.903 31.79 30.76 −1.43 −0.84
Lithuania 3022.716 2852.162 46.30 44.64 −1.62 −1.11
Luxembourg 525.096 589.155 203.05 217.83 2.29 2.19
Hungary 9943.627 9806.949 106.91 105.94 −0.34 −0.21
Malta 419.699 463.933 1330.69 1396.54 0.92 2.93
Netherlands 16,714.000 17,084.920 402.36 407.17 0.38 0.56
Austria 8418.915 8747.861 100.37 102.57 0.46 0.79
Poland 38,045.954 37,979.057 121.68 121.55 0.00 −0.02
Portugal 10,520.638 10,318.674 114.07 112.64 −0.35 −0.24
Romania 20,111.425 19,644.054 84.36 83.26 −0.43 −0.58
Slovenia 2054.513 2068.149 101.34 101.74 0.17 0.22
Slovakia 5402.793 5435.297 110.18 110.57 0.12 0.13
Finland 5401.183 5498.681 15.96 16.16 0.46 0.21
Sweden 9487.973 9988.790 21.63 22.25 0.80 1.22
United Kingdom 63,456.872 65,799.453 261.68 267.50 0.73 0.68
UE-27 441,059.397 445,385.412 104.64 105.25 0.13 0.18
UE-28 504,516.304 511,184.865 113.18 114.08 0.20 0.24
1 Cumulative average annual growth rate. Source: Prepared by authors based on Eurostat.
According to data from the European Commission, the European population had
513,472 million inhabitants in 2019, with an average annual cumulative growth of 0.22%,
a positive evolution in the period analysed. However, this growth has not been similar
in all EU countries. In fact, there is a strong dichotomy between countries with growing
populations and countries with declining ones. Among those seeing population growth are
Malta, Luxembourg, Sweden, Ireland, Cyprus, Austria and the United Kingdom. However,
countries such as Lithuania, Latvia, Bulgaria, Romania, Croatia, Greece, Portugal and
Hungary are on the opposite side, experiencing sharp population reductions.
If we focus our attention on the proportion of the population in the European Union
as a whole, there are also marked differences. Thus, those with the highest percentage of
population include Germany (16%), France (13%), the United Kingdom (12%), Italy (11%),
Spain (9%) and Poland (7%). While Malta (0.08%), Luxembourg (0.10%), Cyprus (0.17%),
Estonia (0.26%), Latvia (0.4%), and Slovenia (0.4%) stand out for their low proportion. In
the period under review, some countries have substantially increased their shares of the EU
population, such as the United Kingdom (by 0.26%) and Germany and France (0.11%), and
some countries have reduced it considerably, such as Romania (by 0.14%), Spain (0.13%)
and Poland (0.11%).
In terms of population density, measured as the ratio between the population of each
country and its surface area in square kilometres, there are considerable disparities. Thus,
EU countries such as Malta, the Netherlands, Belgium, the United Kingdom, Germany,
Luxembourg and Italy have a high-density ratio. Furthermore, of these countries, Malta,
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Luxembourg, Belgium, the United Kingdom, the Netherlands, Italy and Germany increase
this variable, while other countries, such as Finland, Sweden, Estonia, Latvia, Lithuania,
Bulgaria, Ireland, Croatia, Greece and Romania, mostly in Eastern Europe, have a low
density. In addition, many of these countries show losses in population density, such as
Lithuania, Greece, Bulgaria, Romania, Croatia and Latvia. It is interesting that Ireland
is a country with a low population density, but with a growing population in the period
analysed.
This clearly highlights two relevant aspects. Firstly, we can observe the disparate
situation in the distribution of the population, with countries with a high volume of
population compared to others with a low level of this variable. Secondly, we can see
the evolution of the concentration experienced by the population in certain countries of
the European Union, with a widening of the gap between the most densely populated
(generally the countries of Western Europe) and the least densely populated ones (generally
Eastern countries). This will also be reflected in the level of PSH in EU countries.
The dynamics of Gross Domestic Product, together with the evolution of the pop-
ulation, determine the progress experienced by GDP or per capita income (Table 2), the
variable used in this work to assess the level of socio-economic development, as explained
above. If we focus our attention on this aspect, it can be seen that GDP per capita has
grown in the European Union countries as a whole by 1.2% per year cumulatively in the
period under analysis. In this respect, strong divergences can be observed in the level
of economic development of the member states of the European Union. Thus, countries
such as Luxembourg, Ireland, Denmark, Sweden, the Netherlands, Austria, Finland, Ger-
many, Belgium, France and the United Kingdom, have an income level per capita of over
30,000 euros in the period analysed. At the other end of the scale are Bulgaria, Romania,
Croatia, Latvia, Poland, Hungary, Lithuania, Estonia and Slovakia, all Eastern European
countries, with per capita GDP levels generally below 15,000 euros.
The economic and financial crisis of 2007 did not affect all EU Member States in the
same way. Indeed, the countries most affected by this recession were Greece, Cyprus, Italy,
Portugal, Spain, Croatia, Finland and Slovenia, which had negative cumulative average
annual growth rates in the period 2010–2014, the year in which the economic recovery
began. In the period 2015–2019, states that started with a lower GDP per capita grew
at a higher rate. In fact, the countries that experienced the highest growth in the period
indicated were Romania, Ireland, Lithuania, Poland, Hungary, Estonia, Bulgaria, Croatia,
Cyprus, Latvia and Slovenia, practically all from the Eastern European area, and more
recent members of the EU, with a growth of more than 3%. On the opposite side, with a
growth of less than 1.5%, we can find Luxembourg, Sweden, United Kingdom, Belgium,
Italy, Germany, Greece, France and Austria, countries from the West, and older in terms of
the creation of the European Union.
In general, the countries with the highest growth were those that started out with
the lowest level of per capita income in the period analysed (2010–2019), and vice versa.
Therefore, we can deduce a priori that there has been a process of beta convergence in this
decade in the level of economic development in the European Union states as a whole.
According to our initial hypothesis, this level of income per capita will precisely condition
the PSH of the countries of the European Union.
Concerning inequalities in the level of income per capita, based on the application of
the sigma convergence indicator to the GDP per capita of the countries of the European
Union in the period 1995–2019 (Figure 1), we observe that the member states tend to
converge. In other words, they tend to be more equated, especially from 1999 onwards.
There is also a slight upturn in divergence in the period 2008–2010, possibly because of the
impact of the economic crisis, but from the latter year onwards their convergent progress
continues in the period under review.
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Table 2. Gross Domestic Product per capita (2010 constant prices in purchasing power parity).
Countries
GDPpc 1 CAAGR 2
2010–2014 2015–2019 2010–2014 2015–2019
Belgium 33.528 35.094 0.40 1.13
Bulgaria 5.326 6.308 2.30 4.25
Czechia 15.228 17.354 0.76 2.99
Denmark 44.310 47.668 0.59 2.17
Germany 33.134 35.136 1.52 1.23
Estonia 12.258 14.474 4.03 4.28
Ireland 37.456 54.256 2.08 5.00
Greece 17.728 17.194 −4.42 1.28
Spain 22.388 24.276 −0.91 2.22
France 31.110 32.364 0.51 1.34
Croatia 10.394 11.564 −0.50 4.03
Italy 26.188 26.370 −1.43 1.23
Cyprus 21.746 23.036 −3.55 3.98
Latvia 9.576 11.650 4.83 3.77
Lithuania 10.260 12.770 5.68 4.79
Luxembourg 78.646 82.768 0.10 0.71
Hungary 10.262 12.128 1.97 4.29
Malta 17.224 20.960 3.15 2.28
Netherlands 38.490 40.606 0.07 1.68
Austria 36.078 37.106 0.52 1.38
Poland 9.954 11.868 2.66 4.53
Portugal 16.426 17.612 −1.09 2.84
Romania 6.572 8.210 3.23 5.73
Slovenia 17.552 19.378 −0.18 3.57
Slovakia 13.138 15.036 2.06 2.68
Finland 35.016 36.024 −0.50 1.91
Sweden 40.588 43.318 0.76 0.77
United Kingdom 30.386 32.364 1.20 0.88
UE-27 25.144 26.990 0.50 1.92
UE-28 25.808 27.682 0.62 1.77
1 Gross Domestic Product per capita. 2 Cumulative average annual growth rate. Source: Prepared by authors
based on Eurostat.
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period 2010–2019. This clearly indicates a process of beta convergence in the level of GDP
per capita in these countries.
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If we focus on PSH, we can see that it has remained at around 80% of total health
expenditure in the European Union as a whole. Moreover, it has evolved positively from
2014 to 2016. In 2017, its share decreased slightly, rising again slightly in 2018. Therefore,
PSH serves the majority of the population in the EU-28 economy. Therefore, we will try to
analyse the influence of the level of economic development on the evolution PSH in these
countries.
PSH accounts for the largest share in countries such as Sweden, Germany, Luxem-
bourg, Denmark, the Czech Republic, Croatia, the Netherlands and Slovakia, where it
accounts for more than 80% of total health spending (Table 3). At the other end, we can
find Cyprus, Greece, Bulgaria, Latvia, Portugal, Malta, Lithuania and Hungary, where the
share of PSH is less than 70% of total health expenditure. It is interesting to note that in
the period under analysis (2014–2018) there are countries that have significantly increased
the public share of total health spending, such as France with an increase of 7%, Ireland
with almost 3%, Hungary and Malta with just over 2%, Slovenia with 1.7%, and Greece
and Sweden with 1%. In contrast, some countries decrease their share of public health
financing, such as Portugal with a reduction of 4.5%, Estonia with 2%, the United Kingdom
and Italy with just over 1.5% and Finland with 1%.
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Table 3. Public expenditure on health (PSH) in EU Member States (as % of Total Spending on Health).
Countries 2014 2015 2016 2017 2018
Belgium 75.85 75.77 76.10 75.96 75.81
Bulgaria 58.48 56.12 55.36 55.94 59.08
Czechia 82.69 82.37 81.98 82.09 83.03
Denmark 84.19 84.18 84.12 84.02 83.88
Germany 84.21 84.17 84.31 84.52 84.56
Estonia 75.68 75.62 75.66 73.59 73.67
Ireland 71.02 72.04 72.44 72.79 73.89
Greece 57.67 57.58 60.74 60.46 58.75
Spain 70.27 71.32 71.55 70.65 70.40
France 76.54 76.64 83.07 83.27 83.63
Croatia 82.92 82.63 82.52 82.54 82.84
Italy 75.42 74.44 74.40 73.74 73.89
Cyprus 43.05 41.60 41.09 41.35 42.99
Latvia 59.67 58.65 55.87 57.33 59.88
Lithuania 67.56 67.14 66.60 66.14 67.05
Luxembourg 83.48 83.66 83.61 83.95 84.08
Hungary 67.10 68.19 68.10 69.14 69.45
Malta 61.32 60.57 63.03 62.90 63.48
Netherlands 81.08 81.38 81.14 81.65 82.07
Austria 74.01 74.06 73.96 73.98 74.70
Poland 70.66 69.99 69.85 69.29 71.49
Portugal 66.08 66.17 61.48 61.11 61.54
Romania 79.00 78.02 78.33 78.65 79.73
Slovenia 71.11 71.81 72.73 72.20 72.82
Slovakia 80.23 79.72 80.36 79.94 80.13
Finland 78.02 76.94 76.23 76.42 76.92
Sweden 84.03 84.08 84.42 84.76 85.09
United Kingdom 79.47 79.50 79.66 78.69 77.78
UE-27 78.02 78.01 79.38 79.35 79.58
UE-28 78.26 78.27 79.42 79.25 79.31
Source: Prepared by authors based on Eurostat.
The territorial distribution of PSH is closely correlated with the spatial distribution
of the population (Table 4). It is logical to think that expenditure so closely linked to the
population and its structure should be distributed according to this variable. Therefore,
we present the distribution of PSH per inhabitant in the EU countries. This distribution
shows enormous disparities and intense crystallisation, as the ranking has hardly changed
significantly over the period analysed. There are countries with PSH per capita of more than
2000 euros, such as Denmark, Sweden, Luxembourg, Germany, the Netherlands, France,
Ireland, Austria, Belgium, Finland and the United Kingdom. Among these countries with
the highest PSH per capita there are also strong disparities, with countries spending 4000
euros and others spending 2500 euros. On the other hand, some countries have a PSH per
capita of less than 600 euros, such as Bulgaria, Romania, Latvia, Poland, Hungary and
Lithuania, with a huge difference between them, some countries with an expenditure of
250 euros compared to others with 580 euros.
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Table 4. Public Spending on Health (PSH) per capita (millions €—2010 constant prices).
Countries 2014 2015 2016 2017 2018 Av. Growth 1
Belgium 2682.34 2714.71 2709.27 2775.63 2772.66 0.83
Bulgaria 249.14 240.65 250.55 262.81 284.09 3.34
Czechia 972.01 965.52 971.32 1025.09 1123.60 3.69
Denmark 3844.35 3927.61 3987.43 4027.10 4099.46 1.62
Germany 3146.42 3210.81 3276.61 3385.52 3452.66 2.35
Estonia 601.44 638.84 667.84 701.62 740.97 5.35
Ireland 2734.87 2605.96 2687.05 2773.11 2927.68 1.72
Greece 767.19 784.11 851.57 837.77 810.39 1.38
Spain 1417.65 1501.04 1520.81 1541.44 1572.18 2.62
France 2776.21 2772.87 3039.87 3080.57 3107.18 2.86
Croatia 572.54 596.23 625.72 647.26 676.65 4.27
Italy 1700.34 1690.17 1689.25 1694.70 1711.66 0.17
Cyprus 605.86 603.63 623.43 643.78 692.48 3.40
Latvia 335.76 357.86 382.28 397.48 451.30 7.67
Lithuania 472.21 506.21 533.51 545.43 586.64 5.57
Luxembourg 3620.50 3592.53 3612.96 3647.63 3714.93 0.65
Hungary 510.20 524.34 547.03 558.47 580.51 3.28
Malta 1037.74 1074.11 1142.42 1196.00 1214.50 4.01
Netherlands 3305.55 3291.25 3312.30 3345.50 3392.76 0.65
Austria 2771.69 2770.82 2787.03 2843.80 2915.13 1.27
Poland 468.85 489.17 516.59 542.03 568.36 4.93
Portugal 969.44 987.16 985.18 1006.47 1053.27 2.10
Romania 279.26 281.45 300.65 335.67 385.77 8.41
Slovenia 1065.36 1100.15 1143.42 1147.90 1218.21 3.41
Slovakia 753.38 772.55 817.71 810.51 832.12 2.52
Finland 2624.41 2557.71 2525.71 2537.55 2557.66 −0.64
Sweden 3788.12 3865.65 3927.70 3970.17 4058.04 1.74
United Kingdom 2474.22 2498.51 2521.98 2510.31 2539.99 0.66
UE-27 1982.61 2010.66 2081.18 2124.96 2166.52 2.24
UE-28 2046.59 2074.00 2137.41 2174.63 2214.99 2.00
1 Average growth. Source: Prepared by authors based on Eurostat.
In addition, PSH per capita has grown by 2% in the EU-28 member states as a whole in
the period under analysis (2014–2018). However, progress has not been similar in all cases
and there are marked disparities. Indeed, there are countries with high cumulative average
annual growth in the period 2014–2018, such as Romania, Latvia, Lithuania, Estonia,
Poland, Croatia, Malta, the Czech Republic, Slovenia, Cyprus, Bulgaria and Hungary,
countries from the East of the European Union, with a growth of over 3%. On the opposite
side, with a growth of less than 1.5%, are countries such as Finland, which is the only
one to decrease its expenditure by 0.64%, Italy, Luxembourg, the Netherlands, the United
Kingdom, Belgium, Austria and Greece, the oldest countries in the European Union.
The presentation of health spending as a percentage of GDP makes it easier to detect
the rate of growth of both variables (Table 5). In this respect, we can see that there is
practically stagnation between the final period and the initial period analysed in the EU-
28 as a whole. There are countries in the Union in which health spending per GDP is
increasing, while in others this ratio is decreasing. France, Romania, Latvia, Germany,
Estonia, Lithuania and Greece show a growth of more than 0.1%. In contrast, Ireland,
Finland, the Netherlands, Italy, Portugal, Bulgaria, Slovakia, Hungary, the United Kingdom,
Cyprus, Denmark, Belgium and Luxembourg experienced a decrease of more than 0.1%
over the period.
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Table 5. Public Expenditure on Health (PSH) (% GDP).
Countries 2014 2015 2016 2017 2018 Av. Growth 1
Belgium 7.92 7.90 7.83 7.92 7.81 −0.11
Bulgaria 4.51 4.16 4.14 4.16 4.34 −0.17
Czechia 6.28 5.93 5.83 5.86 6.25 −0.03
Denmark 8.56 8.61 8.53 8.44 8.45 −0.12
Germany 9.28 9.41 9.47 9.57 9.67 0.39
Estonia 4.61 4.79 4.86 4.85 4.92 0.31
Ireland 6.85 5.26 5.38 5.15 5.07 −1.78
Greece 4.56 4.65 5.05 4.90 4.66 0.10
Spain 6.38 6.50 6.40 6.31 6.31 −0.07
France 8.86 8.79 9.57 9.51 9.46 0.59
Croatia 5.55 5.61 5.64 5.58 5.62 0.07
Italy 6.69 6.59 6.49 6.40 6.39 −0.30
Cyprus 2.99 2.87 2.80 2.77 2.87 −0.12
Latvia 3.26 3.32 3.43 3.42 3.71 0.44
Lithuania 4.18 4.36 4.42 4.27 4.38 0.20
Luxembourg 4.55 4.42 4.36 4.42 4.45 −0.10
Hungary 4.74 4.68 4.77 4.65 4.58 −0.16
Malta 5.58 5.39 5.64 5.62 5.64 0.06
Netherlands 8.57 8.40 8.32 8.21 8.19 −0.38
Austria 7.67 7.67 7.66 7.68 7.71 0.04
Poland 4.49 4.49 4.60 4.60 4.58 0.09
Portugal 5.96 5.94 5.79 5.70 5.79 −0.17
Romania 3.97 3.86 3.92 4.05 4.43 0.47
Slovenia 6.05 6.12 6.16 5.91 6.02 −0.02
Slovakia 5.53 5.41 5.62 5.41 5.36 −0.17
Finland 7.63 7.42 7.15 6.98 6.95 −0.68
Sweden 9.20 9.08 9.15 9.14 9.27 0.07
United Kingdom 7.91 7.86 7.87 7.74 7.78 −0.13
UE-27 7.81 7.76 7.89 7.85 7.85 0.04
UE-28 7.83 7.78 7.88 7.83 7.84 0.01
1 Average growth. Source: Prepared by authors based on Eurostat.
In terms of PSH as a proportion of GDP, there are huge inequalities between the
countries studied. Thus, countries such as Germany, France, Sweden, Denmark, the
Netherlands, Belgium, the United Kingdom and Austria invest more than 7% of GDP in
public health, although there are wide disparities between them, with differential values
ranging from 7.6 to 9.60% respectively. On the other hand, Cyprus, Latvia, Bulgaria,
Lithuania, Romania, Luxembourg, Poland, Hungary, Greece and Estonia, with spending of
less than 5% of GDP, also have large differences, ranging from 2.8% to 4.9%. Therefore, we
can affirm that there are strong disparities in the investment made by the member states of
the European Union in PSH with respect to their GDP, as well as a great immobilisation of
the countries in the established ranking.
As an indicator of inequality, the figure above shows the Gini index of disposable
income within the EU-28 countries for the years 2010, 2015 and 2019 (Figure 3). We can see
that the Gini Index has increased by 0.002 points in the EU-28 and has remained the same in
the EU-27 as a whole. Moreover, in general, the countries in the East of the European Union
have the highest values of the index, indicating a higher concentration of disposable income.
Countries with a longer history of EU-28 membership have lower values in this index,
reflecting how disposable income is more evenly distributed among their population. We
will use this index to adjust GDP per capita, discounting the effect of internal inequalities,
in order to establish the relationship between PSH per capita and the level of economic
development in the EU-28 member countries, the main object of this scientific research.
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Considering Sustainable Development Goal 10 (Reducing inequalities in the EU-28),
we see that the distribution of disposable income has hardly changed in the period analysed
(2010–2019) acc rding to Eur pean C mmission data. Thus, the poorest 10% of the EU
population has 2.8% of disposabl income, while the richest 10% of the population has 24%
of di posable income. This situation has remained over the ni e years analysed.
Sim larly, it can be seen that he po rest 20 f has only 7.8% of the
income, while the has nearly 40% at its disposal. This demonstrates the strong
socio-ec nomic inequalities that still ex st among the population of the European Union.
A first approximation of the relationship between GDP and PSH is shown in Figures 4 and 5.
These represent the influe ce between these variables n per capita term in the EU-28
member sta es i the period 2014–2018. In Figure 4 we have used GDP per capita, and in
Figure 5 we ave adjusted the level of economic development by discount ng the influence
of the Gini Index presented within the EU-28 member states, in order to penalise those
countries with a high level of GDP per capita, but with a highly concentrated distribution,
and vice versa. In both cases, we found a tendentially increasing relationship between
the two variables, indicating that there seems to have been a close positive and direct
relationship between PSH and the level of economic development in the period analysed.
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Table 6. Influence of the level of economic development on public expenditure on health (per capita)
in the EU-28 Member States (2014–2018).
Regression Model with Panel Data
Dependent Variable: Log(PSHpc 1)
OLS Estimation
Variable
Estimate 1 Estimate 2
Coefficient t-Statistic Coefficient t-Statistic
Constant −5.363574 −15.85622 −4.434975 −14.75819
Log(GDPpc 2) 1.253818 35.79316 - -
Log(GDPpcn 3) - - 1.204515 37.14237
AR(1) 0.431266 7.885517 0.374002 7.597537
R-squared 0.923071 0.924544
Adjusted R-squared 0.922017 0.923510
Durbin-Watson stat 1.988998 1.980670
F-statistic 875.9235 894.4489
n 150 150
1 PSHpc = Public spending on health per capita; 2 GDPpc: Gross Domestic Product per capita (level of economic
development); 3 GDPpcn: Gross Domestic Product per capita net of the effect of income concentration within the
EU-28 Member States. OLS = Ordinary least squares. Source: Prepared by authors based on Eurostat.
The results of the fixed effects estimations based on panel data have been carried out,
on the one hand, considering the level of economic development measured by GDP per
capita as an explanatory factor (model 1) and, on the other hand, applying the adjustment
to the level of economic development by discounting the inequality of the distribution
of disposable income within the EU-28 member states (model 2). The application of the
Hausman test gives a result that favours estimation using fixed effects. The regressions
have been corrected for autocorrelation using a first-order autoregressive (AR(1)) scheme
for the shocks, and for heteroscedasticity using the White procedure. The models are
explanatory and the coefficients are strongly significant.
The regressions presented show that the level of GDP per capita has had a significant
influence on the progress of PSH per capita in the EU-28 member states in the period
under study. The coefficient on this regressor, in both estimations, is positive and highly
significant at a 99% confidence level. This shows that the EU-28 countries with the highest
levels of income are those that invest the most in public health (both measured in per
capita terms).
4. Discussion
In the 1970s, the income level was already considered the main explanatory element
in health expenditure. Indeed, Kleiman and Newhouse empirically demonstrated the close
relationship in per capita terms between health expenditure and GDP. So nearly 90% of the
variation in per capita health expenditure in 13 countries is explained by the variation in
per capita GDP [29,30]. Numerous subsequent papers corroborate the empirical evidence
of the link between aggregate income and health expenditure [31–49]. These findings
have been generalised in studies in European Union countries, in the G7 and the Seven
Emerging Markets (EM7) [50], in the 15 member countries of the Economic Community of
West African States (ECOWAS) [51], and in countries as politically and socially distant as
China and the United States [52]. We found similar positions in all of them. Moreover, not
only is the link between the level of economic development and PSH investigated, but it
has been established that financial development is an essential element of this variable. One
study examines this relationship for a set of 159 countries over the period 1995–2014, using
country-level data. The results show a close relationship between financial development
and PSH and suggest policies to orient financial development towards health care to
maximise the well-being of society [53].
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Determinants of health expenditure include the level of income, the age structure of the
population [54–57], the form of health financing (whether public or private), technological
innovation [58,59], population density [60], the level of the environment [61], the degree of
development of cities, the health coverage of the foreign population [62] and the number of
doctors per person [58]. Widespread ideas in recent studies highlight the suggestions made
to policy planners to maximise public health benefits and environmental quality, which are
closely related to sustainable GDP growth.
Research based on European Social Survey (ESS) data aimed to analyse the char-
acteristics that affect individuals and nations’ health. The most relevant finding is that
personal factors such as age, economic satisfaction, level of education, unemployment,
social networks, and occupational status are linked to men and women’s health. On the
other hand, social factors such as PSH, lifestyle, socio-economic development, and social
capital are related to people’s subjective health. Among the factors at a national level,
socio-economic development measured by GDP per capita (log) is a variable closely related
to improving health after controlling the characteristics individually. Finally, countries
from the East of Europe highlight the worst conditions for health [63].
There are also strong disparities in health spending, as the results of this study have
shown. In a previous study, it was shown that inequalities in PSH were evident in European
Union member states in the period 1995–2010, indicating that these differences had become
entrenched and that income per capita is the main determinant of health expenditure [64].
The impact of the economic crisis has also been relevant for health spending, due to
its relationship with economic development. Indeed, during periods of economic crisis,
PSH has increased to compensate for the reduction in private health spending [65]. Health
spending behaves differently when GDP is growing than when it is decreasing [66]. These
authors highlight that in the former case both public and private health spending increase,
while in the latter case private health spending tends to stagnate while public health
spending tends to increase, as the latter usually compensates for the possible decrease in
private spending. Economic crises often exacerbate the challenges of demographic and
technological change and major health threats. This puts the sustainability of health systems
at risk and calls for the search for alternatives to enable their adequate financing [67–69]. A
population served over time through sustainable health structures is a decisive factor for
economic and social development.
It is also necessary to emphasise studies that highlight the bidirectional influence
between the level of economic development (GDP per capita) and PSH per inhabitant. This
research attempts to show how economic development affects PSH, and how investment
in people’s health also boosts economic development by enabling people to remain active
for longer and in better health [70–73]. Moreover, this public investment in health helps
to reduce inequalities by limiting and hindering poverty and social exclusion [68]. In
short, the findings validate the existence of a co-integrated relationship between economic
growth and PSH, emphasising the bidirectional nature of the cause–effect of these economic
aggregates.
Recently, the Sustainable Development Goals’ (SDG) methods to improve the world’s
socio-economic and environmental conditions have led to the emergence of research that
attempts to link health and well-being (O3) goals with the reduction of inequality (O10)
when considering economic development. In some cases, this indicates an inconsistency
between the health goals of the Sustainable Development Goals and economic growth [74].
In particular, the analysis of three East African countries (Uganda, Malawi, and Tanzania)
concluded that GDP growth, which is an indicator of economic development, does not
automatically benefit medical and health expenditures in different nations. They also
pointed out that the facts have proved that foreign aid is not enough to make up the
funding gap, as are the policy recommendations of the International Monetary Fund (IMF).
International Monetary Fund loans are conditioned on GDP growth, and strict monetary
and fiscal indicators have severely damaged the development of health sector expenditures.
In other words, in these countries, if the government does not take sufficient measures
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to distribute wealth and investment equitably, and the government only focuses on GDP
growth, then the existence of O8 (decent work and economic growth) centered on GDP
may be detrimental, delaying efforts to achieve O3, to promote health and well-being. The
health sector suggests that Governments should pay more attention to O17 (partnership to
achieve goals) in global cooperation [75].
Lately, governments have reaffirmed their commitment to SDGs through the Astana
Declaration, signed on 25 October 2018, which redefines the three functions of primary
health care as service delivery, multisectoral action and citizen empowerment. Indeed, the
health-related SDGs cannot be achieved only through the provision of health services, as
some health issues are linked to other elements such as the environment, which inevitably
requires agreements and joint efforts between local, national and international partners [76].
All of the above questions open up an interesting line of research, such as the creation
of a sustainable health system, with a public health service capacity that allows the entire
population to be adequately cared for. Some studies have already highlighted the situation
in European Union member states [60], as well as the impact that Covid-19 has had on these
countries in recent times. The Covid-19 pandemic has affected billions of people worldwide
and has not only highlighted but also exacerbated the social and economic inequalities of
recent decades [77]. This has caused new research to begin to penetrate the economic and
social impact of the efficiency of research and development (R&D) spending in the health
sector. An interesting study on the changes brought about by advances in research in a
sample of 23 European and OECD countries for the period 2009–2017 concludes that such
investment is transformed into improvements in quality of life, finding that happiness,
national wealth and health spending are the factors with the greatest influence on the
European population’s perception of health [78]. It also indicates that it is necessary to be
prepared to deal with any type of pandemic, such as the one we are currently experiencing,
relying on the implementation of the United Nations Sustainable Development Goals and
investment in health care capital to ensure an efficient allocation of resources in the public
health system [77,78]. However, any intervention that focuses on growing the economy in
a sustainable and durable way must be accompanied by interventions that compensate for
commitments to health, safety and the environment.
5. Conclusions
The aim of this study was to establish the relationship between the level of socio-
economic development of the EU-28 member states and their public expenditure on health
(PHE). This general objective has been broken down into three specific objectives. First, we
have investigated the relationship between PSH and GDP, both in per capita terms. Then,
we have studied the level of convergence experienced by GDP and PSH, both also at per
capita level. Finally, we have analysed the evolution experienced by inequalities in income
per capita, and their influence on the level of PSH in the context of the countries of the
European Union. The following considerations can be drawn from this analysis.
PSH is an aspect with a significant influence on the population as a whole, guarantee-
ing equal opportunities among other issues. Its distribution undoubtedly enables social
and territorial cohesion. In general, the public administrations of the countries with the
highest levels of income per capita in the European Union tend to invest more in public
health, which may be a reflection of the fact that health spending is closely linked to their
economic development. However, the economic crisis of 2008 had a significant impact
on PSH, affecting the population with the least economic resources with greater intensity,
generating a problem of vulnerability that the current COVID-19 pandemic has aggravated.
Researchers show that public investment in health should be a priority objective in any
economy, as it has a positive effect on the population as a whole and reduces inequalities
(O10), and ensures society’s well-being (O3). Countries’ effort in technological moderni-
sation and human capital with a high level of competency enhances the value of health
activity and even environmental improvement due to the lower generation of negative
externalities, improving the sustainability of public health services.
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The distribution of PSH among European geographical areas has been closely related
to the territorial distribution of the population in the period analysed. However, there are
still strong territorial differences in this variable per inhabitant, with member states with
PSH per capita of more than 4000 euros, compared to countries with less than 500 euros.
This situation highlights the difficulty experienced by the convergence of PSH per capita in
the EU-28 member states, making a process of social and economic cohesion impossible.
In the same way, strong disparities can be observed in the investment effort made by the
EU-28 countries in health expenditure in relation to their GDP.
A graphical examination and an econometric analysis show that the level of economic
development (measured by GDP per capita) is a determinant of PSH per capita in the EU
Member States. To this end, two econometric regressions have been developed. In the first,
GDP per capita has been considered as the explanatory variable, and in the second, GDP
per capita has been taken as the regressor, discounting the concentration of income within
the EU-28 countries, as measured by the Gini index. Logically, this has a fundamental
impact on the process of territorial cohesion and on the equality of opportunities sought in
the European economy.
The scientific study carried out shows that it would be advisable to reduce the range of
dispersion between the EU-28 member countries in the level of PSH per inhabitant. To this
end, the determinants of these territorial differences must be identified, as they represent
a real obstacle to guaranteeing equal opportunities in access to this type of services and
to achieving higher levels of well-being in the population, in line with the Sustainable
Development Goals that are the subject of this research (O3 and O10). Furthermore, it
is crucial to establish a system that adequately protects public health services provided
by public administrations in the face of the health crisis and the fall in public revenue
experienced in the EU over the last year.
Some key issues for the future need to be addressed, such as the following: (a) the
sustainability of public investment in health requires medium- and long-term financial
planning, with the resources foreseen in the years of economic prosperity; (b) the high
territorial disparities in PSH must be rigorously controlled as they call into question equal
opportunities policies; (c) a serious and rigorous debate should be opened on the level of
sustainable PSH in the European Union, taking into account the restrictions established by
the high public deficit and the high public indebtedness.
Finally, it should be emphasised that the research does not conclude with these
reflections. It is essential to continue analysing the issue of the distribution of PSH, using
new databases, updating existing ones, and applying different scientific methods, which
will make it possible to contrast and consolidate the ideas put forward in this work.
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